Staclazide 80

Gliclazide is a hypoglycaemic sulfonylurea antidiabetic active substance differing from other related compounds by an N-containing heterocyclic ring with an endocyclic bond.

In type 2 diabetics, gliclazide restores the first peak of insulin secretion in response to glucose and increases the second phase of insulin secretion. A significant increase in insulin response is seen in response to stimulation induced by a meal or glucose.

Pack size Box of 60 tablets
Shelf-life 36 months
Composition Gliclazide
Dosage forms and strengths Tablet: 80 mg
Product code :



  • Non insulin dependent diabetes (type 2) in adults when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose.


  • Initial dose
    The total daily dose may vary from 40 to 320 mg taken orally. The dose should be adjusted according to the individual patient’s response, commencing with 40 – 80 mg daily (½ – 1 tablet) and increasing until adequate control is achieved. A single dose should not exceed 160 mg (2 tablets). When higher doses are required, Staclazide 80 should be taken twice daily and according to the main meals of the day.
    In obese patients or those not showing adequate response to gliclazide alone, additional therapy may be required.
  • Switching from another oral antidiabetic agent to Staclazide 80
    Staclazide 80 can be used to replace other oral antidiabetic agents.
    The dosage and the half-life of the previous antidiabetic agent should be taken into account when switching to Staclazide 80.
    A transitional period is not generally necessary. A starting dose of 40 – 80 mg (½ to 1 tablet) should be used and this should be adjusted to suit the patient’s blood glucose response.
    When switching from a hypoglycaemic sulfonylurea with a prolonged half-life, a treatment free period of a few days may be necessary to avoid an additive effect of the two products, which might cause hypoglycaemia.
  • Combination treatment with other antidiabetic agents
    Staclazide 80 can be given in combination with biguanides, alpha glucosidase inhibitors or insulin.
    In patients not adequately controlled with Staclazide 80, concomitant insulin therapy can be initiated under close medical supervision.

Special populations

  • Elderly
    Using the same dosing regimen recommended for patients under 65 years of age.
  • Renal impairment
    In patients with mild to moderate renal insufficiency, the same dosing regimen can be used as in patients with normal renal function with careful patient monitoring.
  • Patients at risk of hypoglycaemia is recommended to use the minimum daily starting dose of 40 – 80 mg:
    Undernourished or malnourished,
    Severe or poorly compensated endocrine disorders (hypopituitarism, hypothyroidism, adrenocorticotrophic insufficiency),
    Withdrawal of prolonged and/or high dose corticosteroid therapy,
    Severe vascular disease (severe coronary heart disease, severe carotid impairment, diffuse vascular disease).
  • Paediatric population
    The safety and efficacy of Staclazide 80 in children and adolescents have not been established. No data are available.


  • Orally administered.
  • Hypersensitivity to gliclazide or to any of the excipients, other sulfonylureas, sulfonamides,
  • Type 1 diabetes,
  • Diabetic pre-coma and coma, diabetic keto-acidosis,
  • Severe renal or hepatic insufficiency: In these cases the use of insulin is recommended,
  • Treatment with miconazole,
  • Lactation.


  • Hypoglycaemia, if mealtimes are irregular and, in particular, if meals are skipped.
    Possible symptoms of hypoglycaemia are: headache, intense hunger, nausea, vomiting, lassitude, sleep disorders, agitation, aggression, poor concentration, reduced awareness and slowed reactions, depression, confusion, visual and speech disorders, aphasia, tremor, paresis, sensory disorders, dizziness, feeling of powerlessness, loss of self-control, delirium, convulsions, shallow respiration, bradycardia, drowsiness and loss of consciousness, possibly resulting in coma and lethal outcome.
  • Adrenergic counter-regulation. Sweating, clammy skin, anxiety, tachycardia, hypertension, palpitations, angina pectoris and cardiac arrhythmia.
    Usually, symptoms disappear after intake of carbohydrates (sugar). However, artificial sweeteners have no effect. Experience with other sulfonylureas shows that hypoglycaemia can recur even when measures prove effective initially.
    If a hypoglycaemic episode is severe or prolonged, and even if it is temporarily controlled by intake of sugar, immediate medical treatment or even hospitalisation are required.
  • Gastrointestinal disturbances, including abdominal pain, nausea, vomiting, dyspepsia, diarrhoea, and constipation have been reported: If these should occur they can be avoided or minimised if gliclazide is taken with breakfast.


  • This treatment should be prescribed only if the patient is likely to have a regular food intake (including breakfast). It is important to have a regular carbohydrate intake due to the increased risk of hypoglycaemia if a meal is taken late, if an inadequate amount of food is consumed or if the food is low in carbohydrate. Hypoglycaemia is more likely to occur during low-calorie diets, following prolonged or strenuous exercise, alcohol intake or if a combination of hypoglycaemic agents is being used.
  • Hypoglycaemia may occur following administration of sulfonylureas. Some cases may be severe and prolonged. Hospitalisation may be necessary and glucose administration may need to be continued for several days.
  • Careful selection of patients, of the dose used, and clear patient directions are necessary to reduce the risk of hypoglycaemic episodes.
  • Factors which increase the risk of hypoglycaemia:
    Patient refuses or (particularly in elderly subjects) is unable to co-operate,
    Malnutrition, irregular mealtimes, skipping meals, periods of fasting or dietary changes,
    Imbalance between physical exercise and carbohydrate intake,
    Renal insufficiency,
    Severe hepatic insufficiency,
    Overdose of Staclazide 80,
    Certain endocrine disorders: Thyroid disorders, hypopituitarism and adrenal insufficiency,
    Concomitant administration of certain other medicines.

Renal and hepatic insufficiency

  • The pharmacokinetics and/or pharmacodynamics of gliclazide may be altered in patients with hepatic insufficiency or severe renal failure. A hypoglycaemic episode occurring in these patients may be prolonged, so appropriate management should be initiated.

Patient information

  • The risks of hypoglycaemia, together with its symptoms, treatment, and conditions that predispose to its development, should be explained to the patient and to family members. The patient should be informed of the importance of following dietary advice, of taking regular exercise, and of regular monitoring of blood glucose levels.

Poor blood glucose control

  • Blood glucose control in a patient receiving antidiabetic treatment may be affected by any of the following: St. John’s Wort (Hypericum perforatum) preparations, fever, trauma, infection or surgical intervention. In some cases, it may be necessary to administer insulin. The hypoglycaemic efficacy of any oral antidiabetic agent, including gliclazide, is attenuated over time in many patients: this may be due to progression in the severity of the diabetes, or to a reduced response to treatment. This phenomenon is known as secondary failure which is distinct from primary failure, when an active substance is ineffective as first-line treatment. Adequate dose adjustment and dietary compliance should be considered before classifying the patient as secondary failure.


  • Disturbances in blood glucose, including hypoglycaemia and hyperglycaemia have been reported, in diabetic patients receiving concomitant treatment with fluoroquinolones, especially in elderly patients. Indeed, careful monitoring of blood glucose is recommended in all patients receiving at the same time Staclazide 80 and a fluoroquinolone.

Laboratory tests

  • Measurement of HbA1c levels (or fasting venous plasma glucose) is recommended in assessing blood glucose control. Blood glucose self-monitoring may also be useful.

Staclazide 80 contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose – galactose malabsorption should not take this medicine.

Treatment of patients with G6PD-deficiency with sulfonylurea agents can lead to haemolytic anaemia. Since gliclazide belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD-deficiency and a nonsulfonylurea alternative should be considered.

The product is contraindicated in pregnancy and breast-feeding mothers.

Staclazide 80 has no or negligible influence on the ability to drive and use machines. However, patients should be informed that their concentration may be affected if their diabetes is not satisfactorily controlled, especially at the beginning of treatment.